IUC26692-90 Benchmarking Artificial Intelligence-Based Clinical Prediction Models for Immune Checkpoint Inhibitor Response and Overall Survival in Bladder Cancer
Abstract Background Bladder cancer (BLCA) is a common urological malignancy with high recurrence and heterogeneous treatment response. Immune checkpoint inhibitors (ICIs) have transformed advanced BLCA treatment, yet response prediction remains challenging. AI-based models have been developed to predict ICI response an...